LARIN FE 1/20 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Larin Fe 1/20, and when can generic versions of Larin Fe 1/20 launch?
Larin Fe 1/20 is a drug marketed by Novast Labs and is included in one NDA.
The generic ingredient in LARIN FE 1/20 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for LARIN FE 1/20
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LARIN FE 1/20 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LARIN FE 1/20
US Patents and Regulatory Information for LARIN FE 1/20
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novast Labs | LARIN FE 1/20 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 091454-001 | Aug 26, 2013 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |